Evidence map›Paper›PMID 39054374›Full record

Trial reportNature medicine2024

Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial.

Anouk E Hiensch, Johanna Depenbusch, Martina E Schmidt, Evelyn M Monninkhof, Mireia Pelaez, Dorothea Clauss, Nadira Gunasekara, Philipp Zimmer, Jon Belloso, Mark Trevaskis and 26 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04120298 (Effects of Structured and Individualized Exercise in Patients With Metastatic Breast Cancer on Fatigue and Quality of Life), which is not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04120298 naactive not recruitingnot on this map

Effects of Structured and Individualized Exercise in Patients With Metastatic Breast Cancer on Fatigue and Quality of Life

TypeinterventionalSponsorUMC UtrechtRan2020 to 2027Enrolled357ConditionsMetastatic Breast CancerArmsSupervised exercise
3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  9. Physical Exercise in Immunotherapy.Sports medicine - open · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Anouk E Hiensch *Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Johanna Depenbusch *German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT, a partnership between DKFZ and University Medical Center Heidelberg) Heidelberg, Heidelberg, Germany.
Martina E SchmidtGerman Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT, a partnership between DKFZ and University Medical Center Heidelberg) Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2095-2426
Evelyn M MonninkhofJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Mireia PelaezGipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain.
Dorothea ClaussGerman Sport University Cologne, Cologne, Germany.
Nadira GunasekaraGerman Sport University Cologne, Cologne, Germany.ORCID http://orcid.org/0009-0008-5847-7086
Philipp ZimmerTU Dortmund University, Dortmund, Germany.
Jon BellosoGipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain.
Mark TrevaskisMary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
Helene RundqvistDepartment of Laboratory Medicine, Karolinska Institutet and Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-5617-9076
Joachim WiskemannHeidelberg University Hospital and NCT Heidelberg (a partnership between DKFZ and University Medical Center Heidelberg), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5971-5436
Jana MüllerHeidelberg University Hospital and NCT Heidelberg (a partnership between DKFZ and University Medical Center Heidelberg), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-1718-1392
Maike G SweegersNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-4892-4061
Carlo FremdDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7840-430X
Renske AltenaKarolinska Institutet, Unit for Nursing, Karolinska Comprehensive Cancer Center, Breast and Sarcoma Unit, Karolinska University Hospital, Solna, Sweden.
Maciej GoreckiGreater Poland Cancer Centre, Poznan, Poland.
Rhodé BijlsmaDivision of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Lobke van Leeuwen-SnoeksDiakonessenhuis Utrecht-Zeist-Doorn, Utrecht, The Netherlands.
Daan Ten Bokkel HuininkAlexander Monro Ziekenhuis, Bilthoven, The Netherlands.
Gabe SonkeNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8088-9628
Ainhara LahuertaGipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain.
G Bruce MannRoyal Melbourne Hospital, Melbourne, Victoria, Australia.
Prudence A FrancisPeter MacCallum Cancer Centre, The University of Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-7207-9286
Gary RichardsonCabrini Research, Cabrini Health, Malvern, Victoria, Australia.
Wolfram MalterCenter for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Elsken van der WallDivision of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Neil K AaronsonNetherlands Cancer Institute, Amsterdam, The Netherlands.
Elzbieta SenkusMedical University of Gdańsk, Gdańsk, Poland.ORCID http://orcid.org/0000-0001-6855-397X
Ander UrruticoecheaGipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain.
Eva M ZopfMary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
Wilhelm BlochGerman Sport University Cologne, Cologne, Germany.
Martijn M StuiverNetherlands Cancer Institute, Amsterdam, The Netherlands.
Yvonne WengstromKarolinska Institutet, Unit for Nursing, Karolinska Comprehensive Cancer Center, Breast and Sarcoma Unit, Karolinska University Hospital, Solna, Sweden.ORCID http://orcid.org/0000-0001-8317-7829
Karen SteindorfGerman Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT, a partnership between DKFZ and University Medical Center Heidelberg) Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5215-5651
Anne M MayJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. a.m.may@umcutrecht.nl.ORCID http://orcid.org/0000-0003-0643-3790

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 2018/GNT1170698
6 · The paper itself

Abstract

Physical exercise both during and after curative cancer treatment has been shown to reduce side effects. Evidence in the metastatic cancer setting is scarce, and interventions that improve health-related quality of life (HRQOL) are much needed for patients with metastatic breast cancer (MBC). The multinational randomized controlled PREFERABLE-EFFECT trial assessed the effects of exercise on fatigue and HRQOL in patients with MBC. In total, 357 patients with MBC and a life expectancy of ≥6 months but without unstable bone metastases were recruited at eight study centers across five European countries and Australia. Participants were randomly assigned (1:1) to usual care (control group, n = 179) or a 9-month supervised exercise program (exercise group, n = 178). Intervention effects on physical fatigue (European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-FA12 scale) and HRQOL (EORTC QLQ-C30 summary score) were determined by comparing the change from baseline to 3, 6 (primary timepoint) and 9 months between groups using mixed models for repeated measures, adjusted for baseline values of the outcome, line of treatment (first or second versus third or higher) and study center. Exercise resulted in significant positive effects on both primary outcomes. Physical fatigue was significantly lower (-5.3 (95% confidence interval (CI), -10.0 to -0.6), Bonferroni-Holm-adjusted P = 0.027; Cohen's effect size, 0.22) and HRQOL significantly higher (4.8 (95% CI, 2.2-7.4), Bonferroni-Holm-adjusted P = 0.0003; effect size, 0.33) in the exercise group than in the control group at 6 months. Two serious adverse events occurred (that is, fractures), but both were not related to bone metastases. These results demonstrate that supervised exercise has positive effects on physical fatigue and HRQOL in patients with MBC and should be recommended as part of supportive care.ClinicalTrials.gov Identifier: NCT04120298 .

Indexed as

Breast NeoplasmsExercise TherapyFatigueQuality of LifeAdultAgedExerciseFemaleHumansMiddle AgedNeoplasm MetastasisSurveys and Questionnaires

Identifiers

PMID39054374
PMCPMC11485212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.